# Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

> **NCT07551336** · PHASE1 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 36 (estimated)

## Conditions studied

- Malignant Glioma
- High-Grade Gliomas
- Glioblastoma
- Recurrent High-Grade Gliomas
- Recurrent Glioblastoma

## Interventions

- **BIOLOGICAL:** Dual-target CAR-NK cells
- **DRUG:** Cyclophosphamide
- **DEVICE:** Intracranial catheter/reservoir for locoregional delivery
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07551336
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-04-14
- **Final completion:** 2028-04-17
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551336, "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07551336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*